CyGenica
Bangalore, India· Est.
CyGenica leverages its GEENIE protein nanoneedle platform to enable endosome‑bypassing intracellular delivery of next‑generation therapeutics.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
CyGenica leverages its GEENIE protein nanoneedle platform to enable endosome‑bypassing intracellular delivery of next‑generation therapeutics.
OncologyRare Diseases
Technology Platform
GEENIE is an engineered protein nanoneedle that penetrates the plasma membrane and delivers therapeutic cargo directly to the cytosol, bypassing endosomal sequestration.
Opportunities
Strategic partnerships with pharma to apply GEENIE to RNA and protein therapeutics, and expansion into mRNA vaccine and gene‑editing delivery markets.
Risk Factors
Potential immunogenicity, manufacturing scale‑up challenges, and regulatory uncertainty for a novel intracellular delivery platform.
Competitive Landscape
Competitors include lipid nanoparticle and viral vector platforms (e.g., Moderna, Alnylam) and peptide‑based delivery systems; GEENIE differentiates through endosome‑bypassing delivery and protein‑based nanoneedle architecture.